康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景  

Current status of application of convalescent plasma in acute viral infectious diseases and its prospect in therapy of COVID-19

作　　者：杨晓明 侯继峰 YANG Xiao-ming;HOU Ji-feng(China National Biotec Group Company Limited,Beijing 100029,China)

机构地区：[1]中国生物技术股份有限公司,北京100029 [2]中国食品药品检定研究院血液室,北京100029

出　　处：《中国生物制品学杂志》2020年第3期241-245,共5页Chinese Journal of Biologicals

基　　金：国家科技部重点专项“2019-nCoV感染恢复期患者特异性血浆和特异性球蛋白的制备”(2020YFC-0841800)。

摘　　要：随着康复期血浆(convalescent plasma,CP)被成功地用于治疗多种急性病毒性传染病,其独到的治疗技术优势越来越受到肯定和认同。新近在中国武汉发现并鉴定一种命名为2019-nCoV(SARS-CoV-2)的新型冠状病毒,目前暂无特异性治疗其感染的有效手段。本文就CP应用于埃博拉、大流行流感、严重急性呼吸综合征(severe acute respiratory syndrome,SARS)、中东呼吸综合征(Middle East respiratory syndrome,MERS)的现状作一综述,并对其治疗新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)的前景作一展望。With the successful application of convalescent plasma(CP) in various acute viral infectious diseases,the unique advantage of the therapy has been paid more and more attentions. Recently,a novel coronavirus named as 2019-nCoV(SARS-CoV-2)was discovered and identified in Wuhan,China. Up to now,there has been no specific treatment for 2019-nCoV(SARS-CoV-2) infection. This paper describes the current status of application of CP in Ebola,pandemic influenza,severe acute respiratory syndrome(SARS) and Middle East respiratory syndrome(MERS) as well as the prospect of CP in therapy of COVID-19.

关 键 词：康复期血浆 大流行流感病毒 埃博拉病毒 SARS冠状病毒 MERS冠状病毒 新型冠状病毒 新型冠状病毒肺炎 

分 类 号：R457.2[医药卫生—治疗学] R373.1[医药卫生—临床医学]